Results 271 to 280 of about 76,984 (297)
Some of the next articles are maybe not open access.
TACROLIMUS AND MYOCARDIAL HYPERTROPHY
Transplantation, 2000Tacrolimus has been used as an immunosuppressive agent in the transplantation of all solid organs. Tacrolimus-induced hypertrophic cardiomyopathy has been reported to be an unusual but serious complication. To elucidate the effects of tacrolimus on myocardial hypertrophy, we studied the relationship between the blood levels of tacrolimus and cardiac ...
Shinji Uemoto +6 more
openaire +3 more sources
Meltdose Tacrolimus Pharmacokinetics
Transplantation Proceedings, 2016Nonadherence to immunosuppressive therapy contributes to the loss of grafts. One of the problem is the fractioning of immunosuppressive dose. In fact, it was demonstrated that a single daily dose (QD) is associated with an increased adherence to therapy compared with twice daily dosing (BID).
openaire +3 more sources
Tacrolimus in cardiac transplantation
Expert Review of Clinical Immunology, 2007The availability of effective immunosuppressive agents has allowed cardiac transplantation to become an accepted treatment for patients with end-stage heart disease. In recent years, tacrolimus has emerged as a useful alternative to cyclosporine, combined with either azathioprine or the newer antiproliferative agents, mycophenolate mofetil or sirolimus.
Jon A. Kobashigawa, Jignesh Patel
openaire +3 more sources
Journal of the American Academy of Dermatology, 2004
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial.
Irina V. Haller +2 more
openaire +3 more sources
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial.
Irina V. Haller +2 more
openaire +3 more sources
Tacrolimus in transplant rejection
Expert Opinion on Pharmacotherapy, 2012Renal transplantation is the best therapy for patients with end-stage renal disease. To avoid graft rejection, adequate immunosuppressive therapy is crucial. Tacrolimus is approved for prophylaxis of transplant rejection in liver, kidney or heart allograft recipients and for the treatment of allograft rejection resistant to treatment with other ...
openaire +3 more sources
CYCLOSPORINE AND TACROLIMUS IN DERMATOLOGY
Dermatologic Clinics, 2001Immune modulators are being used with increasing frequency in dermatology. This article reviews two such agents, cyclosporine and tacrolimus. Discussion emphasizes the pharmacology, side effects, and uses of these two drugs in dermatologic disorders.
Jennifer Clay Cather +2 more
openaire +2 more sources
Tacrolimus as an Immunomodulator
2004The immunopharmacological modulation of the immune response plays a key role in transplantation medicine. During the first 30 years of organ transplantation glucocorticosteroids and cytotoxic substances, such as azathioprine and cyclophosphamide, were the drugs most frequently used to prevent graft rejection. The introduction of cyclosporin in the year
T. Assmann, T. Ruzicka, B. Homey
openaire +2 more sources
Ranolazine-Tacrolimus Interaction
Annals of Pharmacotherapy, 2010Objective: To report the case of a kidney allograft recipient on a stable regimen of tacrolimus who exhibited increased tacrolimus concentrations within 24 hours of initiating ranolazine. Case Summary: A 64-year-old kidney allograft recipient on a stable dose of tacrolimus (10 mg twice daily) was admitted for recent worsening of her chronic anginal ...
Dwayne A. Pierce, Amber Reeves-Daniel
openaire +2 more sources
Clinical Pharmacokinetics of Tacrolimus
Clinical Pharmacokinetics, 1995Tacrolimus, a novel macrocyclic lactone with potent immunosuppressive properties, is currently available as an intravenous formulation and as a capsule for oral use, although other formulations are under investigation. Tacrolimus concentrations in biological fluids have been measured using a number of methods, which are reviewed and compared in the ...
Arun Swaminathan +9 more
openaire +3 more sources
Tacrolimus in heart transplantation
Transplantation Proceedings, 2003Tacrolimus (Tac), which blocks T- and B-cell proliferation by inhibiting calcineurin, was first used for immunosuppression following heart transplant (HT) in 1989. Two multicenter randomized trials have compared Tac to the oil-based cyclosporine (CsA) formulation (both combined with azathioprine and steroids) in HT patients.
openaire +3 more sources